Hykin, P., Prevost, A. T., Sivaprasad, S., Vasconcelos, J. C., Murphy, C., Kelly, J., . . . Brazier, J. (2021). Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: The LEAVO non-inferiority three-arm RCT. Health Technol Assess.
Chicago-tyylinen lähdeviittausHykin, Philip, et al. "Intravitreal Ranibizumab Versus Aflibercept Versus Bevacizumab for Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Non-inferiority Three-arm RCT." Health Technol Assess 2021.
MLA-viiteHykin, Philip, et al. "Intravitreal Ranibizumab Versus Aflibercept Versus Bevacizumab for Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Non-inferiority Three-arm RCT." Health Technol Assess 2021.